FX-909, a first-in-class investigational oral small molecule inhibitor of peroxisome proliferator-activated receptor gamma ...

Median disease-free survival (DFS) increased from 4.8 months with placebo to 9.9 months with adjuvant atezolizumab (Tecentriq ...

The first iteration of HER2-targeted drugs showed limited activity in bladder cancer, but the rise of antibody-drug ...

While Natera said it will seek FDA approval for Signatera based on data from IMvigor011, the readout from another ctDNA-guided de-escalation study was more nuanced.

Patients with muscle-invasive bladder cancer who test positive for circulating tumor (ct)DNA after surgery to remove the ...

Patients with muscle-invasive bladder cancer have varied outcomes after cystectomy. Circulating tumor DNA (ctDNA)–based detection of molecular residual disease may identify patients at high risk ...

This is the first meta-analysis comparing the overall survival of patients with limited-stage small cell bladder cancer who underwent radical surgery with platinum-based perioperative chemotherapy vs ...

Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that it has entered into a partnership with Intelligent Scopes Corporation (ISC) to develop Artificial Intelligence (AI) software with ...

Interstitial cystitis is a chronic bladder condition that can cause pelvic pressure and pain. Lifestyle changes, medication, and surgery can treat IC.

Bladder cancer is one of the most common urological cancers, with nonmuscle invasive forms accounting for a significant portion of new diagnoses. In September, UC Davis Comprehens ...